Treatment of cavitary and infiltrating pulmonary tuberculosis with and without the immunomodulator Dzherelo.

An open-label, 60-day trial was conducted in 75 newly diagnosed tuberculosis (TB) patients to assess the adjunctive effect of the oral immunomodulator Dzherelo with standard anti-TB chemotherapy (ATT) consisting of izoniazid, rifampicin, pyrazinamide and streptomycin (HRZS) administered as directly observed therapy (DOT). Group 1 (n = 28) with cavitary TB and group 2 (n = 17) with infiltrating pulmonary TB received 50 drops of Dzherelo twice daily in addition to HRZS. Group 3 (n = 30), which served as a control, received ATT only. Liver damage indicators, bilirubin, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) decreased to normal levels in groups 1 and 2, but increased significantly in group 3. Kidney failure markers, urea and creatinine, normalized in Dzherelo recipients, but were unchanged or worsened in the ATT-only group. The changes in serum lactate dehydrogenase, catalase, malondialdehyde and diene conjugates suggested that Dzherelo downregulates TB-associated inflammation. The anti-inflammatory property of Dzherelo was further supported by a favourable haematology profile, reduced erythrocyte sedimentation rate and faster defervescence. Radiological recovery was significant in both Dzherelo groups, but not in the control group (p = 0.0085, p = 0.025 and p = 0.23, respectively). These findings correlated positively with sputum smear conversion and clinical findings (r = 0.94; p < 0.05). Mycobacterial clearance at day 30 was observed in 77%, 72% and 40% of patients in groups 1, 2 and 3, respectively. After 2 months sputum conversion rates in groups 1, 2 and 3 were 93%, 89% and 70%, respectively. Sixty-day treatment outcomes in groups 1, 2 and 3 as assessed by improvement in clinical features and respiratory function attained respective p-values of 0.008, 0.25 and 0.72, and 0.013, 0.48 and 0.0015. Dzherelo is thus useful as an immunotherapeutic adjunct in the management of TB.

[Phytoconcentrates "dzherelo" and "lizorm" in therapy of autoimmune thyroiditis]. / Fitokontsentraty "dzherelo" ta "lizorm" v likuvanni autoimunnoho tyreoïdytu.

Treatment of patients with autoimmune thyroiditis with phytoconcentrates dzherelo and lizorm has been shown to improve the patients general well-being, alleviate gross manifestations of the condition, impede the development of the autoimmune process. The above therapy is well-tolerated, has no hepato-/nephrotoxic effect, causes no functional/structural disturbances, and does not affect the sizes of the thyroid gland. The phytoconcentrates dzherelo and lizorm can be recommended as treatment of autoimmune thyroiditis (euthyroid state, mild hypothyroisis, in those settings where activity of the autoimmune process is not very high.

[Phytopreparation Diabetin in treatment of patients with insulin-independent diabetes mellitus]. / Fitopreparat "Diabetyn" v likuvanni khvorykh z insulinonezalezhnym tsukrovym diabetom.

The phytopreparation "Diabetin" has a sugar-reducing, anorexigenic effects, facilitates loss of flesh lowering the body mass, causes the manifestations of diabetic angio- and neuropathies to delay. It is recommended as treatment of a mild form of diabetes as monotherapy or in moderately severe course of the trouble it can be used in combination with other peroral sugar-lowering drug preparations.